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Abstract 
Numerous epidemiological, clinical and preclinical studies have shown that 
selenium (Se) has chemopreventive and chemotherapeutic effects against prostate 
cancer. Selenocompounds naturally exist in inorganic and organic forms. The 
chemopreventive activities of Se depend on the dose and form of the compound. 
Organic Se has been found more bioavailable than inorganic Se. In our previous 
studies, we have shown selenocystine (SeC), an organic Se, as a novel agent with 
broad-spectrum anticancer activity. We also demonstrated that SeC was the most 
potent anticancer agent among the organic Se studied. Moreover, SeC showed low 
cytotoxicity to normal human fibroblast Hs68 cells. In the present study, we showed 
that treatment of human prostate carcinoma LNCaP cells with SeC resulted in dose-
and time-dependent apoptotic cell death. SeC induced apoptosis in LNCaP cells via 
extrinsic and intrinsic apoptotic pathways, as indicated by activation of initiator 
caspase-10 and -9，followed by activation of effector caspase-7 and -3, cleavage of 
poly (ADP-ribose) polymerase (PARP)，nuclear condensation, and DNA 
fragmentation. Furthermore, pretreatment with general caspase inhibitors 
significantly prevented the accumulation of sub-Gl cells in subsequent SeC 
treatment. This result suggested that SeC triggered caspase-dependent apoptotic 
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pathway in LNCaP cells. 
Moreover, SeC induced the depletion of mitochondrial membrane potential 
(A中m) in LNCaP cells by regulating the expression of pro-survival and 
pro-apoptotic Bcl-2 family members. In addition, exposure of LNCaP cells to SeC 
resulted in an increase expression in total p53, p-p53 (Ser 15) and p-p53 (Ser 392). 
Activation of p53 up-regulated the pro-apoptotic factors including Puma, Noxa, and 
Bax, and down-regulated the pro-survival factor Bcl-2. Furthermore, time-course 
study showed that significant increase in superoxide was detected in the LNCaP cells 
treated with SeC for 5 miii, indicating that superoxide generation was the upstream 
cellular event induced by SeC. Moreover, ERK, JNK, p38 MAPK and Akt were 
activated via phosphorylation by SeC. Pretreatment with inhibitors of Akt 
(LY294002) and JNK (SP600125) affected apoptosis induced by SeC. However, 
inhibitors of ERK (U0126) and p38 MAPK (SB203580) did not alter the 
apoptosis-inducing effect of SeC. NAC significantly suppressed the generation of 
superoxide, MAPKs and PDK/Akt signalling pathways, and apoptotic cell death. 
Taken together, SeC induced superoxide-mediated apoptosis by regulating MAPK 
and PDK/Akt signalling pathways in LNCaP cells. Our results demonstrated SeC as 
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Chapter 1 Introduction 
1.1. General introduction of cancer 
Cancer is a common and serious threat to the world population. According 
to the report, Cancer Facts and Figures, published by the American Cancer Society in 
2008, there were about 1,437,180 new cases diagnosed of cancer. Each day, more 
than 1,500 people were died of cancer in the US. Cancer is a group of genetic 
diseases in which abnormal cells grow and divide uncontrollably and obtain the 
ability to spread to other tissues or organs via lymph and blood. 
The transformation of a normal cell to a malignant cell, i.e. carcinogenesis, 
is a result of a series of genetic mutation in the affected cells. For instance, the FLIP 
(Fas-associated death domain-like inhibitory proteins), which is an inhibitor of 
CD95/TNF-R1 death signaling, is over expressed in melanoma (Zornig et al., 2001). 
And the tumor suppressor gene p53 is mutated and inactivated in the cases of most 
human cancers (Lebedeva et al., 2003; Zornig et al., 2001) leaving the damaged 
DNA unrepaired. Both external factors, such as radiation and carcinogens, and 
internal factors, such as inherited mutations, cause genetic alteration in the affected 
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cells. Once cells acquire the ability to divide infinitely without normal growth signal, 
escape from apoptosis, induce angiogenesis, and metastasize to other regions of the 
body, the cells become malignant (Hanalian et al.’ 2000). According to the instability 
of genetic information in the cancer cells, strategies aiming at restoring the altered 
genome of the defective cells or eliminating the immortal cells have been extensively 
studied for developing new drugs in cancer therapy (Lebedeva et al., 2003; Nachmias 
et a l , 2004). 
1.2. Overview of apoptosis 
111 all multicellular organisms, cell division and cell death are tightly 
regulated in a homeostasis status. Old cells or damaged cells are removed actively 
and replaced with newly produced cells. Apoptosis, which is one type of program 
cell deaths, is utilized by a cell to commit suicide when the damaged genetic 
information cannot be repaired (Majno et al., 1995). Numerous studies have 
demonstrated that many anticancer drugs exert inhibitory effects on cancer cells 
mainly by activating the key components of apoptosis and thereby restoring the 
program (Herr and Debatin, 2001). 
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Apoptosis is distinguished from other types of cell death by its distinctive 
morphological and biochemical characteristics. The morphological changes of 
apoptosis start from chromatin condensation, nuclear fragmentation and cell 
shrinkage. Then, intact membrane-bounded apoptotic bodies consisting of cellular 
organelles and nuclear fragments are formed; and the process is followed by the 
budding of the plasma membrane. Finally, the apoptotic bodies are phagocytized by 
neighboring cells or macrophages (Kerr et al., 1972). 
Apoptosis is executed through two pathways: the extrinsic death receptor 
pathway and the intrinsic mitochondrial pathway (Chen and Wang, 2002). Both 
pathways are initiated by activating the caspase signaling cascade. Caspases is a 
group of cysteine proteases which cleave specific protein substrates at the aspartate 
residues (Herr and Debatin, 2001). All members of caspase, made of an enzymatic 
region and a prodomain, are produced as inactive proform. In order to be activated, 
the caspase must be cleaved at the aspartate residues. The caspases are classified as 
two groups, the initiator caspase (caspase-8, -9, -10) and the effector caspase 
(caspase-3, -7). Initiator caspases are cleaved by autoactivation, while effecter 
caspases are activated by the initiator caspase members (Haunstetter and Izumo, 
1998). Once activated, the caspases can cleave a wide spectrum of proteins leading to 
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the morphological changes of an apoptotic cell. 
1.2.1. The extrinsic death receptor pathway 
Caspase-8 and -10 are the initiator caspase of the death receptor pathway. 
Before the initiator caspase is activated, ligation of ligand (FasL, TNF-a, Apo-3L 
and TRAIL) with its specific death receptor (Fas, TNFRl, DR3, DR4 and DR5) 
located on the plasma membrane (Kiechle and Zhang, 2002) is required. After the 
binding of ligand to the death receptor, adaptor molecules like FADD or TRADD 
links with the activated death receptor to form a death inducing signaling complex 
(DISC). Then procaspase-8 and -10 proteins are recruited to the DISC and undergo 
autoactivation to release the active form of caspease-8 and -10 (Scaffidi et al., 1998). 
Active caspase-8 and -10 can activate the downstream effector caspases which in 
turn cleave specific protein substrates leading to apoptosis. 
1.2.2. The intrinsic mitochondrial pathway 
The intrinsic pathway is mediated by the release of cytochrome c from the 
mitochondrion. Mitochondrion is triggered to lose the membrane potential by various 
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cellular stress including DNA damage and hypoxia. The increasing membrane 
permeability of the mitochondrion allows the release of cytochrome c into the 
cytoplasm (Herr and Debatin, 2001). Then, cytochrome c, Apaf-1 and procaspase-9 
are induced to form a complex called apoptosome (Shi, 2006). The concentration of 
procaspase-9 proteins enables their autoactivation, and then an effector caspase 
cascade is proteolytically activated, which finally leads to apoptosis. The 
permeability of mitochondrial membrane is tightly regulated by the BcI-2 family 
proteins. This family of proteins can be divided into two subgroups: the pro-
apoptotic members (Bax，Bad, Bik, Bak, Bid, Bim, Noxa, Puma etc.) and anti-
apoptotic members (Bcl-2, Bcl-xL, Mcl-l, etc.). The two groups of proteins 
counteract with each other to control the mitochondrial membrane potential 
(Hengartner, 2000). 
1.2.3. Cross-talk between the intrinsic and extrinsic pathways 
The two apoptotic pathways are independent of each other under most 
conditions; however, crosstalk between them exists in some situations (Hengartner, 
2000). The pro-apoptotic Bid which is cleaved by caspase-8 and -10 translocates 
from the cell surface to the mitochondrion and binds to Bak and/or Bak to facilitate 
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the release of cytochrome c into the cytosol, thereby transmits the death signal from 
cell surface to the mithchondion (Herr and Debatin, 2001). 
1.3. Overv iew of selenium (Se) 
Selenium (Se), a metalloid, was first discovered in 1818 by Berzelius. It is a 
trace element with essential biological functions for both human beings and animal 
species (Rayman, 2000; Schwarz and Foltz, 1957). Se plays an important role in 
controlling normal cell growth and division, operating the immunological function, 
preventing infertility in man, and inhibiting the carcinogenesis of various cancers 
(Arthur et a l , 2003; Rayman, 2000). 
The biological functions of Se are believed to be mediated by selenoproteins, 
in which selenium is incorporated into the proteins as the amino acid 
selenocysteine during translation (Stadtman, 1996). Besides, Se is also incorporated 
into proteins as the form of selenomethionine where selenium replaces the sulfur in 
methionine. So far, 25 selenoproteins have been identified in human such as the 
glutathione peroxidases, thioredoxin reductases and selenoprotein P (Kryukov et al. 
2003). 
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1.3.1. Se and prostate cancer 
Prostate cancer is the most commonly diagnosed cancer in men of most 
western countries. Recently, the incidence rates of prostate cancer have risen rapidly 
in most countries including the low-risk Asian populations (Hsing et al., 2000; Sim 
and Cheng, 2005). A number of epidemiological studies, preclinical cell line and 
animal investigation and clinical trials have revealed Se as one of the most promising 
agents with chemopreventive and chemotherapeutic effects against prostate cancer. 
i. Epidemiological studies 
Many epidemiological studies suggest that high Se levels in the body are 
associated with the decreased incidence of prostate cancer. A case-controlled 
epidemiological study followed 33,737 men for 7 years comparing their toenail 
selenium levels with the incidence of advanced prostate cancer. The men who had 
the highest level of Se had a 65% lower probability of developing advanced prostate 
cancer than those with the lowest level of Se (Yoshizawa et al., 1998), The result was 
similar to a prospective cohort study conducted in the Netherlands for 6.3 years 
(Brandt et al., 2003). The Physicians' Health Study initiated in 1982 followed 22,071 
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healthy male physicians for 13 years. The association between the incidence of 
advanced prostate cancer and prediagnostic plasma Se level was evaluated. The men 
with the highest Se levels were 48% less likely to develop advanced prostate than 
men with the lowest levels of Se (Li et al., 2004). The inverse relationship between 
Se and prostate cancer aroused interest in clinical and preclinical trials of 
chemopreventive effect of Se. 
ii. Clinical trials 
The strongest evidence for the efficacy of Se as a chemopreventive agent 
comes from the Nutritional Prevention of Cancer (NPC) Trial carried out by Clark el 
al. NPC Trial was a randomized, double-blind and placebo-controlled clinical trial 
aiming at investigating the effects of Se supplementation on the prevention of cancer 
in patients with a history of skin carcinoma (Clark el al., 1996). In the Eastern United 
States, 1312 randomly selected patients received 200 |ig selenized yeast or placebo 
per day from 1983 to 1993. Scientists observing on the primary end points found that 
Se supplementation did not reduce the incidences of skin carcinomas. However, 
patients receiving selenized yeast had a 63% lower incidence of prostate cancer 
(Clark et al., 1998). The NPC trial aroused public interest in the action mechanisms 
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of Se in inhibiting prostate cancer. Duffield-Lillico et al. later extended the NPC trial 
to 1996 to complete the blinded phase of the trial. The effect of Se supplementation 
in reducing the incidence of prostate cancer remained significant (Duffield-Lillico et 
a l , 2002). 
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was 
inspired by the NPC trial. The SELECT was a big scale randomized and controlled 
trial designed to study the effect of Se and vitamin E on prostate cancer prevention 
from 2001 to 2004. 35,533 healthy men from the U.S., Canada and Puerto Rico were 
randomly divided into 4 groups receiving Se, vitamin E, Se plus vitamin E, or 
placebo, ^-selenomethionine was used as the seleiiocompound in this trial. In 2008, 
after a follow-up of 5.46 years, since neither Se or vitamin E or combination of these 
two compounds could significantly reduce the prostate cancer incidence and there 
was a non-significant increased incidence of prostate cancer in the vitamin E group 
and type 2 diabetes mellitus in the Se group, the trial was stopped (Lippman et al. 
2009). 
However, the abandoned SELECT trial could not discredit the positive 
effect of Se in preventing prostate cancer shown in Clark's trial. There are a number 
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of reasons. First, in SELECT,丄-selenomethionine was used; however, selenzied 
yeast was used in Clark's work. There might be other chemopreventive 
seleiiocompounds apart from selenomethionine present in the yeast. Second, the 
rising risk of diabetes was not statistically significant. Third, the study groups in 
SELECT were healthy men but patients with a history of skin carcinoma were 
studied in Clark's work (Micke et al., 2009). Therefore, more studies on the effective 
selenocompound candidates and the action mechanisms of Se should be carried out 
before applying Se in prostate cancer treatment. 
iii. Preclinical investigations 
Epidemiological studies identified an inverse relationship between Se level 
in human body and prostate cancer incidence. Human clinical trials provided 
evidences supporting the role of Se as a promising chemopreventive agent against 
prostate cancer. Therefore, many preclinical investigations elucidating the molecular 
mechanisms of Se for treating prostate cancer emerged. 
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a. in vivo studies 
There were more than 100 animal studies investigating the chemopreventive 
effects of Se in vivo. Most of the studies showed a decrease of tumors incidence 
(including prostate tumor incidence) in the animal models (Whanger et al., 2004). 
Several action mechanisms by Se in reducing prostate tumors have been proposed. 
Venkateswaran et al. utilized the 12T-10 Lady transgenic mice, which 
spontaneously developed prostate adenocarcinoma, as model to study the 
chemopreventive effect of Se. Male Lady transgenic mice were fed with standard diet 
or high fat diet alone or supplemented with antioxidant mixture (selenomethionine, 
vitamin E and lycopene) for 24 weeks. At the end of the trial, the mice receiving 
antioxidants had a significantly lower chance of developing prostate cancer 
(Venkateswaran et al, 2004). 
In another study, methylseleninic acid and methylselenocysteine were found 
to inhibit the prostate carcinogenesis significantly in TRAMP mice by delaying 
lesion progression, reducing proliferation and inducing apoptosis through caspase 
activation and DNA fragmentation (Wang et al., 2009). Both methylseleninic acid 
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and methylselenocysteine were also found to inhibit the growth of prostate cancer 
xenograft by reducing the androgen receptor and prostate-specific antigen expression 
significantly (Lee et al., 2006). 
b. in vitro studies 
Although epidemiological studies, human clinical trials and preclinical 
animal investigations showed the chemopreventive activities of Se in treating 
prostate cancer, the molecular action mechanisms of Se have not been fully 
elucidated. Therefore, current Se research interest is focusing on its action 
mechanisms. In vitro cell culture is a useful technique to determine how prostate 
cancers are inhibited by Se. The potential action mechanisms of Se have been 
suggested as inducing DNA damage, oxidative stress and apoptosis; enhancing the 
immune system; inhibiting cell cycle progression, metastasis and angiogenesis; and 
regulating the AR signaling (Jackson and Jr, 2008; Nadiminty and Gao, 2008; 
Whanger et a l , 2004). 
Among the suggested mechanisms, apoptosis is the most important mode of 
action by Se; there have been many in vitro results demonstrating the ability of Se in 
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inducing apoptosis in prostate cancer cells (Sinha and El-Bayoumy, 2004). More 
than 90 % of the selenium researches used selenite and selenomethionine to test the 
effect of Se compounds in inhibiting tumor growth. Selenite and selenomethionine 
were found to induce apoptosis in LNCaP human prostate cancer cells accompanied 
with chromosome condensation, nuclear fragmentation and cleavage of Poly (ADP-
ribose) polymerase (PARP). Selenomethionine also induced LNCaP cells arresting in 
the G2-M phase (Menter et al., 2000; Zhong et al.，2001). Apoptosis caused by 
selenite was found to be mitochondria-mediated. Swelling of mitochondria, loss of 
cristae and depletion of were also observed in selenite treated LNCaP cells 
(Jiang et al., 2004; Xiang et al., 2009; Zhong et al., 2001). Oxidative stress and 
caspase activation were always associated with selenite induced apoptosis (Xiang et 
al., 2009; Zhong et al., 2001). Although the in vitro studies enhanced the 
understanding of the apoptotic pathway, more works have to be done to fully 
elucidate the detailed action mechanisms by Se. 
c. Selenocystine and prostate cancer 
Selenocystine (SeC) (Figure 1)，a dimer of organic selenocysteiiie, exhibited 
strong toxicity to various cancer types in a number of studies. Li et al. compared the 
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inhibitory effects of sodium selenite, selenomethionine, semethylselenocysteine and 
SeC supplementation on the growth of nitrosamine-induced lung tumors in A/J 
mouse. Only the group of mouse supplemented with SeC had a significant 38% 
reduction of lung tumor incidence (Li et al , 2005). 
SeC also exhibited in vitro toxicity to a number of cancer cell lines 
including human leukemia HL-60 cells, human hepatoma HepG2 cells, human breast 
carcinoma MCF-7 cells and human melanoma A375 cells (Batist et al , 1986; Chen 
and Wong, 2008a; Chen and Wong, 2009b; Kim et al., 2003). Batist et al. compared 
the antitumor activity of selenite, selenate, selenomethionine and SeC on HL-60 cells. 
Only selenite and SeC showed cytotoxicity on HL-60 cells, but the IC50 for 24 h of 
selenite was 3-fold higher than that of SeC (Batist et al., 1986). SeC was also found 
to activate the mitochondrial-mediated apoptosis in A375 cells (Chen and Wong, 
2008a). Apart from inducing apoptosis, Chen and Wong demonstrated that SeC also 
caused MCF-7 cells arresting at S-phase (Chen and Wong, 2009b). Moreover, SeC 
was found to induce superoxide generation in HepG2 cells in order to cause 
apoptosis (Kim et al., 2003). In addition, our previous studies compared the 
antiproliferative effect of SeC with other selenocompounds (sodium selenite, sodium 
selenate, selenomethionine and semethylselenocysteine) on various human cancer 
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cell lines. The results demonstrated that SeC and selenite could significantly induce 
apoptosis in a broad spectrum of human cancer cell lines. Moreover, selenite exerted 
strong toxicity on normal human fibroblast Hs68 cells which was not observed in 
SeC-treated normal cells (Chen and Wong, 2009a). Therefore, SeC was a potent 
selenium candidate in cancer therapy. 
1.4. Object ive 
Most epidemiological studies, clinical trials and preclinical investigations 
suggest Se as potential anticancer agent for treating prostate cancers. As reviewed by 
Nadiminty and Gao, the dose and form of Se are critically important. Various form 
of selenocompounds showed different efficacy in inhibiting prostate cancer cell 
growth. Naturally, Se compounds exist in two forms: the inorganic forms such as 
selenite and selenate; and the organic forms including selenomethionine, 
selenocysteine and selenomethylselenocysteine (Figure 1) (Nadiminty and Gao, 
2008). One of the major goals of Se research is to search for a less toxic form of Se 
compound which still has chemopreventive effect. By comparing the organic and 
inorganic Se compounds, organic Se compounds are generally better tolerated, less 
toxic to normal prostate cells and still effective in inhibiting prostate cancer cell 
15 
growth (Chen and Wong, 2009a; Menter et al., 2000; Nadiminty and Gao, 2008). 
And the bioavailability of organic Se compounds is higher than that of inorganic 
forms (Daniels, 1996). 
Therefore, the organic SeC which has been demonstrated to exert strong 
toxicity to cancer cells is considered as a potent chemopreventive agent. Despite its 
potential in inhibiting a number of human cancer cell lines, the anticancer effect of 
SeC on prostate cancer has never been reported. In the present study, the inhibitory 
effect of SeC on the growth of human prostate adenocarcinoma PC-3 cells and 
human prostate carcinoma LNCaP cells were studied, and the action mechanisms of 
SeC against LNCaP cells were elucidated. Previous studies indicated that apoptosis 
is critical for anticancer effect of Se (Sinha and El-Bayoumy, 2004). We therefore 
evaluated SeC inhibitory effects on the growth and apoptosis of prostate cancer cells 
by using MTT assay, flow cytometric analysis, TUNEL assay, DAPI staining and 
western blot analysis. Several researches demonstrated that SeC induced reactive 
oxygen species (ROS) or superoxide generation upstream of apoptosis in various 
cancer cell lines (Chen and Wong, 2008a; Chen and Wong, 2009b; Kim et al., 2003). 
We also investigated whether SeC caused oxidative stress in prostate cancer cell, 
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Chapter 2 Materials and methods 
2.1. Materials 
Selenocystine (SeC) was purchased from Sigma (CAT no. SI650). 4丨，6-
Diamidino-2-phenyindole (DAPI), propidium iodide (PI), bovine serum albumin 
(BSA) and solid JC-1 were purchased from Sigma. The Pan-caspase inhibitor (z-
VAD-fmk) was obtained from Calbiochem. z-DEVD-fmk (caspase-3/-7 inhibitor), z-
lETD-fmk (caspase-8 inhibitor) and z-LEHD-fmk (caspase-9 inhibitor) were 
purchased from Merck. Bicinchoninic acid kit for protein determination, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), dihydroethidium 
(DHE), L-glutathione reduced (GSH) and N-acetylcysteine (NAC) were obtained 
from Sigma. 
Lysis buffer and all antibodies were obtained from Cell Signaling 
Technology (Beverly, MA). RPMI 1640 medium for cell culture was from Invitrogen 
Corp. (Carlsbad, CA). Fetal bovine serum (FBS), penicillin and streptomycin were 
purchased from Gibco BRL (Gaithersburg, MD). Water used in the study was 
ultrapure, supplied by Millipore Milli-Q water purification system. 
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2.2. Methods 
2.2.1. Cell culture 
Human prostate adenocarcinoma PC-3 cells and human prostate carcinoma 
LNCaP cell line were purchased from American Type Culture Collection (ATCC, 
Manassas, VA) and maintained in RPMI 1640 medium supplemented with 10% FBS, 
100 units/mL penicillin and 50 units/mL streptomycin in a fully humidified incubator 
with 5% CO2 at 37�C. The cell lines were passaged 2 times per week. 
2.2.2. MTT assay 
MTT assay was performed to determine the cell viability by measuring the 
ability of cells to convert yellow MTT to purple formazan salt (Mosmaiin, 1983). 
Cells were pre-seeded in 96-well flat bottom tissue culture plate for 24 h. The cells 
were then incubated with different concentration of SeC for 24 h, 48 h, and 72 h 
respectively. After incubation period, 20 uL of MTT solution was added into each 
well which was then incubated for 5 h. Then, the medium was removed and 150 
uL/well of dimethylsulfoxide (DMSO) was added to dissolve the formazan products. 
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The colour intensity of the purple formazan solution was measured by a microplate 
spectrophotometer (SpectroAmax丁^ 250) at wavelength 570 nm. 
2.2.3. Cell cycle distribution analysis 
The cell cycle distribution was analyzed using flow cytometry as described 
previously (Chen and Wong, 2008a). After treatment with SeC, LNCaP cells were 
collected, washed with phosphate buffered saline (PBS) and fixed with 75% ethanol 
at -20OC overnight. The fixed cells were then washed with PBS, 1% BSA and stained 
with PI staining solutions for 4 li in dark. The stained cells were analyzed by an 
Epics XL-MCL flow cytometer (Beckman Coulter, Miami, FL). MultiCycle software 
(Phoenix Flow Systems, San Diego, CA) was used to analyze the cell cycle 
distribution. Sub-Gl cells in the cell population represented apoptotic cells with 
hypodiploid DNA content. For all flow cytometric analysis, data of 10000 events per 
sample were recorded. 
2.2.4. TUNEL assay and DAPI staining 
Cells were pre-seeded in chamber slides for 24 h and treated with SeC for 
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various period of time. After treatment, the cells were fixed with 3.7% formaldehyde 
for 10 min and then permeabilized with 0.1% Triton X-100 in PBS. Then, the cells 
were incubated with 100 |iL/chamber of TUNEL reaction mixture which contains 
nucleotide mixture and terminal deoxynucleotidyl transferase (TdT) for 1 h and with 
1 |ig/mL DAPI solution for 15 min at 37°C respectively. After incubation, the cells 
were washed with PBS and analyzed by a fluorescence microscope (Nikon Eclipse 
80i). 
2.2.5. Evaluation of mitochondrial membrane potential (A^m) 
Cells were harvested after the treatment, then washed with PBS and 
suspended in 0.8 mL of PBS containing 10 |xg/mL of JC-1. After incubating at 
humidified environment at 37°C for 30 min, cells were centrifuged to remove the 
supernatant. Then, the remaining cell pellets were resuspended in PBS and analyzed 
by a flow cytometry immediately. Cells losing A^m were represented by the 
percentage of the green fluorescence from JC-1 monomers. 
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2.2.6. Measurement of superoxide generation (DHE assay) 
Level of intracellular superoxide was measured using adapted method from 
our previous study (Chen and Wong, 2009a). After treatment, cells were incubated 
with DHE at a final concentration of 10 |iM for 25 min at 37°C. Then, cells were 
trypsinized, centrifuged to remove the supernatant and resuspended in PBS. The 
level of superoxide was measured by a flow cytometry. 
2.2.7. Inhibition of superoxide generation 
The intracellular superoxide generation was inhibited by using two different 
types of antioxidant including GSH and NAC. The pre-seeded LNCaP cells were pre-
treated with 2mM of GSH or NAC respectively 2 hours prior 24 h of SeC treatment. 
After the SeC treatment, the LNCaP cells were incubated with DHE at a final 
concentration of 10 jiM for 25 min at 37°C. Then, cells were trypsinized, centrifuged 
to remove the supernatant and resuspended in PBS. The level of superoxide was 
measured by a flow cytometry. 
22 
2.2.8. Western blot analysis 
Collected cells were extracted with lysis buffer for Ih on ice. The protein 
concentration of the cell lysates were measured using the bicinchoninic acid kit from 
Sigma. 40 |ig of proteins per sample was loaded on SDS-PAGE gel (12%) and 
analyzed by Western blotting. After electrophoresis, the separated proteins were 
transferred from the gel to a nitrocellulose membrane. After blocking the membrane 
with 5% non-fat milk in TEST for 1 h，primary antibodies with optimal dilution were 
added and incubated at 4°C overnight. Then, membrane was incubated with 
horseradish peroxidase conjugated secondary antibodies for 1 h at room temperature. 
The protein bands on membrane were visualized on X-ray film using a 
chemiluminescence system (Kodak). The present study used primary antibodies 
against caspase- 3，-7, -8，-9, -10, PARP, Bad, Bak，Bax, Bcl-2, Bcl-xL, Bid, Mcl-l, 
Noxa, Puma, p21Wafl, p53, p-p53-(Ser 6)，p-p53-(Ser 9), p-p53-(Ser 15), p-p53-(Ser 
20)，p-p53-(Ser 37), p-p53-(Ser 46)，p-p53-(Ser 392), p38 MAPK, p-p38 MAPK, 
p44/42, p-p44/42, Akt, p-Akt, JNK, p-JNK, and (3-actin. 
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2.2.9. Statistical analysis 
Data were expressed as mean 士 SD of three separate experiments. Statistical 
analysis was performed using two-tailed Student's t-test when comparing the 
difference between two groups; and one-way ANOVA when comparing more than 
two groups. P<0.05 or P<0.01 was considered statistically significant. 
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Chapter 3 Results 
3.1. The antiproliferative effect of SeC on L N C a P and PC-3 cells 
To examine the effect of SeC on LNCaP cells and PC-3 cells, both cell lines 
were incubated with different concentration of SeC for 24 h, 48 h, and 72 h 
respectively. MTT assay was used to determine the cell viability after SeC treatment. 
As shown in Fig. 2, SeC reduced cell viability of both cell lines in a dose- and time-
dependent manner. LNCaP cells were more sensitive to SeC treatment than PC-3 
cells. For LNCaP cells, the IC50 of SeC were 7.3 [iM at 48 h and 3.8 \iM at 72 h, and 
the IC50 were 17.4 |iM at48 h and 10.9 i^M at 72 h in PC-3 cells. 
Observing under a light microscope, both LNCaP cells and PC-3 showed a 
reduction in cell number after incubating with SeC (Fig. 3). However, apoptotic 
morphological changes such as cell shrinkage, cell rounding and apoptotic bodies 
were only observed in LNCaP cells indicating that apoptosis was induced by SeC in 
LNCaP cells. 
Apoptosis is the major mechanism of Se anticancer action (Sinha and El-
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Bayoumy, 2004), we first assessed whether apoptosis was involved in the inhibitory 
action of SeC against the prostate cancer cell lines using flow cytometric analysis. 
Cells were treated with 5, 10, 20，40 or 80 i^M SeC for 24 h respectively, and then 
stained with PI. Sub-Gl population in the cells were analyzed and measured by flow 
cytometry. 
As shown in Fig. 4, SeC induced a dose-dependent generation of siib-Gl 
population in LNCaP cells. SeC at 5 |iM concentration already caused significant 
formation of sub-Gl cells in LNCaP cells, and the effect further strengthened at 
higher concentration of SeC. On the other hand, there was no significant induction of 
sub-Gl population in PC-3 cells treated with SeC up to 80 \iM concentration. Apart 
from inducing sub-Gl cell formation, the flow cytometric results also revealed that 
SeC caused a slight increase of the S-phase in the LNCaP cells. The SeC-induced 
sub-Gl peak generation in LNCaP cells was time-dependent (Fig. 5). Significant 
sub-Gl peak occurred after 24 h treatment of 20 |iM SeC and increased with longer 
incubation time. The results implied that SeC induced apoptosis in LNCaP cells but 
not in PC-3 cells. 
To confirm the apoptotic induction effect of SeC on LNCaP cells, TUNEL 
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assay and DAPI staining were performed. As shown in Fig. 6, nuclear condensation 
and DNA fragmentation happened in LNCaP cells after incubating with SeC for 24 h. 
The protein level of PARP, a hallmark of apoptosis, in SeC-treated LNCaP cells and 
PC-3 cells were determined using western blot analysis (Fig. 7), the expression level 
of PARP in PC-3 cells remained constant while proteolytic cleavage of PARP 
occurred in LNCaP cells. These results indicated that SeC induced apoptosis in 
LNCaP cells. Therefore, LNCaP cells were chosen for further study of the anticancer 
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Figure 2. SeC inhibited the growth of PC-3 and LNCaP cells. Cell viability of PC-3 
cells (A) and LNCaP cells (B) after treating with different concentrations of SeC for 
24, 48, and 72 li as measured by MTT assay. The results were obtained from three 
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Figure 3. Morphological changes of PC-3 cells and LNCaP cells after incubating 
with SeC for 48 h as observed under light microscopy. (A) There was no apoptotic 
morphological change observed in PC-3 cells. (B) SeC induced cell rounding, 
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Figure 5. Quantitative analysis of apoptotic cell death (sub-Gl cells) induced by SeC 
in LNCaP cells using flow cytometry. SeC-induced formation of sub-G2 cells in a 
time-dependent manner. At 24 h of treatment, SeC already caused significant 
apoptotic cell death in LNCaP cells. The results were obtained from three 
independent experiments, **P<0.01 represent significant difference from 
corresponding control. 
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Figure 6. DNA fragmentation and nuclear condensation in LNCaP cells exposed to 
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Figure 7. PARP cleavage in PC-3 and LNCaP cells as detected by western blot after 
treatment of SeC for 24 h. (A) Expression level of PARP in PC-3 cells remained 
constant. (B) PARP was significantly cleaved in LNCaP cells. The results were 
obtained from three independent experiments. 
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3.2. The role of caspases in SeC-induced apoptosis 
To evaluate the involvement of caspase in SeC-induced apoptosis, western 
blot analysis was used to assess the proteolytic expression of caspase family 
members. As shown in Fig. 8, effector caspase-3 and -7 were significantly cleaved 
after exposing LNCaP cells to SeC for 24 h. The protein level of initiator caspase-8 
remained at the same status. SeC caused significant and slight cleavage of initiator 
caspase-9 and -10 respectively which indicated that both intrinsic and extrinsic 
apoptotic pathways were activated. 
Time-course study (Fig. 9) on the activation of caspase family members 
showed that caspase-9 expression level significantly decreased at 8 h of SeC 
treatment; protein level of caspase-10 started to decline slightly at 8 h and remained 
constant until 24 h of treatment. Expression level of caspase-8 kept constant 
throughout the time-course study. Caspase-3 and -7 showed significant cleavages at 
12 h. PARP, the main target of caspase-3, was dramatically cleaved at 8 h, and 
completely cleaved at 24h. 
To determine the importance of caspases as well as the extrinsic and 
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intrinsic apoptotic pathways in SeC-induced apoptosis, pan-caspase inhibitor z-VAD-
fmk, caspase-3/-7 inhibitor z-DEVD-fmk, caspaase-8 inhibitor z-IETD-fmk and 
caspase-9 inhibitor z-LEHD-fmk were used before adding SeC into LNCaP cells. As 
shown in Fig. 1 OA, pretreatment of the caspase inhibitors significantly prevented the 
formation of sub-Gl population in SeC-treated LNCaP cells. The results indicate that 
apoptosis induced by SeC in LNCaP cells was caspase-dependent. Moreover, 
pretreatment with z-IETD-fmk and z-LEHD-fmk significantly suppressed the SeC-
induced apoptosis, indicating that both extrinsic and intrinsic apoptotic pathways 
were involved in the action of SeC. However, z-LEHD-fmk showed better effect in 
protecting LNCaP cells than z-IETD-fmk, suggested that the intrinsic mitochondrial 
pathway played a more important role in SeC-induced apoptosis. The results were 
further confirmed by light microscopy observation, which showed that cells 
争 
pretreated with caspase inhibitors had a reduction in shrinkage of membrane, 
rounding of cells, and formation of apoptotic bodies (Fig. lOB). 
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Figure 8. Western blot analysis of expression levels of caspase-3, -7, -8, -9, and -10 
in LNCaP cells after treatment of SeC for 24 h. SeC triggered activation of caspase-3, 
-7, 9, and -10. Caspase-8 was not cleaved with SeC treatment. The results were 
obtained from three independent experiments. 
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Figure 9. Time-course study of expression levels of caspase-3, -7, -8，-9, -10 and 
PARP in LNCaP cells after treatment of 20 |iM SeC for different hours as examined 
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Figure 10. SeC induced caspase-dependent apoptosis in LNCaP cells. LNCaP cells 
were pretreated with 60 fiM caspase inhibitors 2 h before treatment of 20 pM SeC 
for 24 h. (A) Caspase inhibitors prevented SeC-induced sub-Gl cells formation as 
detected by flow cytometry. (B) The morphological changes were examined under 
light microscopy. The results were obtained from three independent experiments. 
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3.3. T h e e f fec t of S e C on the mitochondria l m e m b r a n e potential 
( A ^ m ) 
Since the intrinsic apoptotic pathway was activated by SeC, the effect of 
SeC on mitochondria was then examined. Cells incubated with various doses of SeC 
for 6 h were stained with JC-1 dye and analyzed by flow cytometry. Red 
fluorescence represents cells with normal A中m，while green fluorescence represents 
cells losing A中m. As shown in Fig. 11, SeC induced a significant dose-dependent 
depletion of A中m in LNCaP cells. Induction of A^m depletion by SeC was also 
time-dependent. Significant decrease of A^m occurred at 1 h in LNCaP cell treated 
with 20 i^ M SeC; A平m further decreased with longer treatment time. 
The membrane potential of mitochondria was strictly regulated by the Bcl-2 
family members. Pro-apoptotic Bcl-2 family proteins counter-act with pro-survival 
Bcl-2 family proteins to control the A平m. The expression level of different Bcl-2 
family proteins in LNCaP cells after 24 h SeC treatment using western blot analysis 
was then examined. Expression of pro-apoptotic Bcl-2 family proteins such as Bax, 
Puma, Bak, Bad and Bid, and pro-survival Bcl-2 family proteins including Bcl-2, 
Mcl-l and Bcl-xL were studied. As shown in Fig. 12, SeC significantly increased the 
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expression levels of Bax and Puma, and suppressed the expression level of Bcl-2. 
SeC also moderately suppressed the protein level of Mcl-l and increased the protein 
level of Bak. In addition, the expression levels of Bcl-xL and Bad were not changed 
obviously. The western blot results suggested that SeC-induced depletion of A^m 
was mainly associated with down-regulation of Bcl-2/Bax or Puma expression ratio. 
Moreover, Bid was cleaved in a dose-dependent manner with SeC treatment. 
Truncated Bid could transmit the apoptotic death signal from cell surface to 
mitochondria indicating the existence of cross talk between the extrinsic and intrinsic 
apoptotic pathways in SeC-treated cells. 
The time-course study (Fig. 13) revealed a temporal expression (up-
regulated or down-regulated) sequence of the Bcl-2 family proteins. After 1 h of SeC 
treatment, Puma and noxa were up-regulated and Bcl-2 was down-regulated. 
Increase in Bax protein level could then be detected after 2 h of treatment. After 4 h, 
Bid was truncated followed by up-regulated expression of Bak at 8 h. Moreover, the 
protein level of Mcl-l decreased at 8 h. Expression level of Bad was also up-
regulated at 8 h but then decreased at 12 h. In addition, protein level of Bcl-xL 
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Figure 12. SeC induced alteration of expression levels of the Bcl-2 family in LNCaP 
cells. (A) Analysis of expression levels of Bax, Puma, Bak, Bad and (B) Bcl-2, Mcl-1, 
Bid and Bcl-xL expression levels in LNCaP cells after treating with different 
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Figure 13. Time-course study of expression levels of Bcl-2 family members in 
LNCaP cells treated with 20 SeC. Analysis of expression levels of (A) Bax, 
Puma, Bak, Noxa, Bad and (B) Bcl-2, Mcl-l, Bid and Bcl-xL in LNCaP cells after 
treating with 20 [xU SeC for 1 h, 2 h, 4 h, 8 h, 12 h and 24 h. The results were 
obtained from three independent experiments. 
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3.4. The involvement of p53 in SeC-treated L N C a P cells 
Our previous studies showed that p53 phosphorylation was involved in SeC-
induced apoptosis in skin and breast cancer cells (Chen and Wong, 2008a; Chen and 
Wong, 2009b). Western blot analysis was performed to investigate the expression and 
phosphorylation status of p53 in LNCaP cells treated with SeC for 24 h. As shown in 
Fig. 14, SeC induced a significant increase in expression level of p53 in a dose-
dependent manner. In addition, p21Wafl, the downstream target of p53, also showed 
increased expression level. Therefore, the results confirmed the activation of p53 
protein by SeC in LNCaP cells. Also, p53 was found to be significantly 
phosphorylated at Ser 15 and Ser 392 in LNCaP cells after SeC treatment. Moreover, 
phosphorylation at Ser 6, Ser 9，Ser 20, Ser 37 and Ser 46 could not be observed 
(data not shown). The time-course analysis (Fig. 15) showed that total p53 protein 
was dramatically up-regulated as early as 1 h of SeC treatment. Phoshorylation of 
p53 at Ser 15 and Ser 19 were also detected at 1 h of treatment. These results 
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Figure 14. SeC induced altered expression levels of p53 and phosphorylated p53 in 
LNCaP cells. SeC triggered up-regulation of (A) total p53, p21Wafl, (B) p-p53-(Ser 
15) and p-p53-(Ser 392). LNCaP cells were treated with different concentration of 
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Figure 15. Time-course study of regulation of expression status and phosphorylation 
of p53, p-p53-(Ser 15), p-p53-(Ser 392) and p21Wafl in LNCaP cells. Cells were 
treated with 20 |aM SeC for different period of time. The results were obtained from 
three independent experiments. 
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3.5. M A P K s and PI3K/Akt signaling pathways 
To examine the involvement of mitogen-activated protein kinases (MAPKs) 
and Phosphoinositide 3-kinase (PI3K)/Akt signaling pathways in regulating 
apoptotic inducing effect of SeC on LNCaP cells, we assessed the effects of SeC on 
the expression status and phosphorylation of MAPSs and Akt. As shown in Fig. 16， 
SeC treatment triggered differential activation of extracellular signal-regulated kinase 
(ERK), c-Jun NH2-terminal protein kinase/stress activated protein kinases 
(JNK/SAPKs), p38 MAPK and Akt signaling pathways. 
Activation of ERK could only be detected after 8 h of treatment, and 
decreased slightly thereafter. The onset of JNK phosphorylation began after 1 h of 
treatment, became significant at 4 h and reached the peak at 8 h. It was then 
decreaseing progressively afterwards. p38 MAPK had a sustaining activation from 1 
h to 12 h, followed by a decline at 12 h. And Akt had a steady increase of 
phosphorylation level throughout the time-course study. On the other hand, SeC did 
not affect the expression level of total ERK, JNK, p38 MAPK and Akt. 
To further examine the significance of these MAPKs and Akt on the 
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inhibitory effect of SeC in LNCaP cells, we pretreated the cells with specific 
inhibitors of the kinases before adding SeC. The results in Fig. 17 and 18 showed 
that only JNK inhibitor (SP600125) and Akt inhibitor (LY294002) had impact on the 
SeC-induced apoptosis. Inhibiting JNK completely suppressed the SeC-induced cell 
death with reducing apoptosis in LNCaP cells. In contrast, Akt significantly reduced 
cell viability and increased the formation of apoptotic bodies in LNCaP cells. These 
results suggested that JNK and Akt played important roles in regulating SeC-induced 
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Figure 16. Time-course study analyzing effects of SeC on phosphorylation status and 
expression levels of ERK, JNK and p38 MAPK and Akt in LNCaP cells incubated 
with 20 i^ M SeC. The results were obtained from three independent experiments. 
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Figure 17. Effects of SP600125 (JNK inhibitor) and LY294002 (PI3K inhibitor) on 
viability of LNCaP cells. Cells were pretreated with 20 piM of different inhibitors 1 h 
prior to the treatment with 20 ^M SeC for 24 h. Pretreatment of SP600125 
completely prevented the apoptosis induced by SeC, and pretreatment of LY294002 
significantly reduced cell viability of LNCaP cells. Cell viability was measured by 
counting cell numbers.Bars with different characters are statistically different with P 
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Figure 18. Effects of SP600125 (JNK inhibitor) and LY294002 (PI3K inhibitor) on 
morphology of LNCaP cells. (A) Pretreatment of SP600125 suppressed SeC-induced 
apoptotic cell death. (B) Pretreatemnt of LY294002 enhanced SeC-induced apoptotic 
cell death. Cells were pretreated with 20 //M of different inhibitors 1 h prior to the 
treatment with 20 /^ M SeC for 24 h. The results were obtained from three 
independent experiments. 
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3.6. T h e role of superoxide in SeC-induced apoptosis 
Superoxide has been shown associated with apoptosis induced by Se 
compounds (Hu et al., 2006; Xiang, et al., 2009). To assess whether superoxide is 
involved in SeC-induced apoptosis, intracellular superoxide level in SeC-treated 
LNCaP cells was measured. The treated cells were stained with DHE and analyzed 
by flow cytometry. Data shown in Fig. 19 and 20 indicated that SeC caused 
remarkable dose- and time-dependent generation of superoxide in LNCaP cells. 
Significant generation of superoxide was observed as early as 5 min of SeC treatment, 
the level of superoxide remained constant until 45 min of SeC treatment, and then 
• continues to increase and peaked at 12 h of treatment, afterward, the level of 
superoxide decreased. The results suggested superoxide played an upstream role in 
SeC-induced apoptosis. 
To further determine the role of superoxide in SeC-induced apoptosis, we 
first used GSH and NAC, two antioxidants, to study its effects on superoxide 
formation in LNCaP cells. GSH could not inhibit the formation of superoxide in the 
LNCaP cells (Data not shown). However, pretreatment of 2 mM NAC could 
effectively prevent superoxide production in SeC-treated cells (Fig. 21). 
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We then investigated the effects ofNAC on the growth of SeC-treated cells. 
N AC could significantly restrict the inhibitory effect of SeC on the growth of LNCaP 
cells (Fig 22). The formation of apoptotic bodies, cell shrinkage and rounding were 
reduced by NAC pretreatment (Fig. 23A). As shown in Fig. 23-25, NAC could 
protect LNCaP cells from SeC-induced apoptosis. The pretreatement of NAC could 
prevent sub-Gl cells formation, A^m depletion, caspase-3,-7, and -9 activation, and 
PARP cleavage in SeC-treated cells. Moreover, the activation of ERK, JNK, p38 
MAPK and Akt were suppressed by NAC as shown in Fig. 26. Superoxide 
generation was therefore important and necessary in SeC-induced apoptosis and 
activation of the MAPK and Akt pathways in LNCaP cells. 
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Figure 19. Intracellular superoxide generation in LNCaP cells after treatment with 
different concentrations of SeC for 24 h. The results were obtained from three 
independent experiments. Bars with different characters are statistically different 
with P < 0.05 
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Figure 20. Time-course study on the intracellular superoxide generation in LNCaP 
cells after treatment of 20 \iM SeC. The results were obtained from three independent 
experiments. Bars with different characters are statistically different with P < 0.05. 
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Figure 21. Pretreatment of 2 mM NAC 2 h prior to the treatment with 20 fiM SeC for 
5 min effectively inhibited the generation of superoxide in LNCaP cells. The results 
were obtained from three independent experiments. Bars with different characters are 
statistically different with P < 0.05. 
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Figure 22. NAC prevents cell growth inhibition induced by SeC. Cells were 
pretreated with 2 mM NAC for 2 h, followed by treatment of 20 juM SeC for 24 h, 
and subjected to measurement of cell viability by counting cell. The results were 
obtained from three independent experiments. Bars with different characters are 
statistically different with P < 0.05. 
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Figure 23. Pretreatment of NAC prevented apoptosis induced by SeC in LNCaP cells. 
(A) Changes of cell morphology observed under light microscopy. (B) Analysis of 
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Figure 24. Pretreatment of NAC suppressed disruption of induced by SeC in 
LNCaP cells. Cells were incubated with 2 niM NAC 2 h prior to the treatment with 
20 /^M SeC for 2 h and measured A中m by flow cytometry The results were obtained 
from three independent experiments. 
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Figure 25. Effects of NAC pretreatment on expression levels of caspase-3, -7，-9 and 
PARP in LNCaP cells as determined by western blot. Cells were incubated with 2 
mM NAC 2 h prior to the treatment with 20 ；wM SeC for 24 h. The results were 
obtained from three independent experiments. 
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Figure 26. Effects of NAC pretreatment on expression levels of MAPKs and Akt in 
LNCaP cells as determined by western blot. Pretreatment of NAC inhibited the 
phosphorylation of ERK, JNK, p38 MAPK and Akt in LNCaP cells. Cells were 
pretreated with 2 mM NAC for 2 h, followed by treatment of 20 /^ M SeC for 24 h. 
The results were obtained from three independent experiments. 
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Chapter 4 Discussion 
The NPC trial by Clark (Clark et al., 1998) has provided the most exciting 
evidence for the role of Se as a chemopreventive agent in treating prostate cancer. In 
Clark's trial, selenized yeast was used as the Se source which contains 85 % 
selenomethionine in the total selenocompound mixture (Ip et al., 2000). Inspired by 
the NPC trial, the big scale SELECT was established to study the effect of 
supplementation of selenomethionine to prevent prostate cancer but later abandoned 
due to the fact that no significant protective effect was observed. Thus, finding the 
effective candidates of selenocompounds in treating prostate cancer is of crucial 
importance. 
The present study demonstrated that SeC was a novel selenocompound 
exhibiting anticancer effect on human prostate carcinoma LNCaP cells. The 
underlying mechanisms of SeC in inhibiting LNCaP cells were elucidated. We 
demonstrated that SeC induced caspase-dependent apoptosis in LNCaP cells via 
mediating A中m, p53 phosphorylation and superoxide generation. JNK and PI3K/Akt 
signaling pathways were also involved in the inhibitory effects of SeC on LNCaP 
cells. ‘ 
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In the present study, firstly we investigated the inhibitory effects of SeC on 
the growth of two human prostate cancer cell lines (LNCaP cells and PC-3 cells). 
The data showed that LNCaP cells were more sensitive to SeC. MTT results showed 
that IC50 of SeC at 48 h and 72 h on LNCaP cells were more than 2-folds lower than 
those of PC-3 cells (Fig. 2). By comparing the morphology of the cells after exposure 
to SeC for 48 h under microscope, the growths of both cells were inhibited. However, 
the apoptotic characteristics, such as cell shrinkage, cell rounding and formation of 
apoptotic bodies, were only found in LNCaP cells (Fig. 3). The difference in 
susceptibility of the PC-3 cells and LNCaP cells toward SeC might be due to the p53. 
PC-3 cells are p53 mutant while LNCaP cells are p53 wild type. Fig. 14 showed that 
SeC induced the upregulation and phosphorylation of p53 which in-turn triggered the 
lost of A4^m in LNCaP cells. The absence of p53 in PC-3 cells might be responsible 
for the cell line being not sensitive to the apoptotic inducing effect of SeC. 
SeC-induced apoptosis was further supported by the significant elevation of 
Sub-Gl cells, nucleus condensation, DNA fragmentation, and PARP cleavage found 
in LNCaP cells exposed to SeC (Fig. 4-7). However, PC-3 cells did not show 
observable increase in Sub-Gl cells and cleavage of PARP, indicating that SeC did 
not cause apoptosis in PC-3 cells. These findings suggested that apoptotic-inducing 
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effect of SeC was cell type specific. In addition to inducing apoptosis, SeC was also 
shown to slightly arrest the LNCaP cells in s-phase of the cell cycle (Fig 4). The 
result was consistent with our previous finding which demonstrated that SeC induced 
s-phase arrest and apoptosis of MCF-7 cells (Chen and Wong, 2008b). However, SeC 
seems to induce cell cycle arrest in a different way in LNCaP cells compared to other 
selenium compounds. Selenomethylselenocysteine was found to arrest LNCaP cells 
non-specifically; and selenomethionine was found to induce LNCaP cells arresting in 
the G2/M phase of cell cycle (Nadiminty and Gao, 2008). 
Apoptosis is the most important mechanism by Se acting on prostate cancer 
(Sinha and El-Bayoumy, 2004). Apoptosis could be executed through two pathways: 
the extrinsic death receptor pathway and the intrinsic mitochondrial pathways (Chen 
and Wang, 2002). Caspases are considered as the central executioners of apoptosis. 
The caspase family proteins play crucial roles in initiating, executing and amplifying 
the apoptotic signals in both pathways. Extrinsic apoptotic pathway is initiated by the 
ligation of ligand to death receptor which leads to the formation of DISC containing 
the death receptor, adaptor proteins and caspase-8/-10. For the intrinsic apoptotic 
pathway, loss of A平m allows the release of apoptotic factors such as cytochrome c 
into the cytosol, cytochrome c together with Apaf-1 and caspase-9 form apoptosome 
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that lead to activation of caspase-9 and then initiate the mitochondrial apoptotic 
pathway (Chen and Wang, 2002). Activation of the caspase cascade cleaves a number 
of proteins that ultimately lead to apoptosis. 
Our data suggested that both extrinsic death receptor pathway and intrinsic 
mitochondrial pathways were activated due to the proteolytic cleavage of caspase-9 
and -10 which then activated the effector caspase-7 and -3 (Fig. 8). The pretreatment 
of caspase inhibitors significantly suppressed the formation of Sub-Gl cell 
population and apoptotic bodies in LNCaP cells indicated the dependent role of 
caspases in SeC-induced apoptotic pathway (Fig. 10). The finding was consistent 
with other studies that reported the predominant role of caspases in Se-induced 
apoptosis (Chen and Wong, 2008a; Jiang et al , 2004). However, the failure of the 
pan-caspase inhibitor to completely prevent SeC from inducing apoptosis in LNCaP 
cells indicated that there was a minor caspase-independent apoptotic pathway. 
Moreover, data in Fig. 10 also suggested that the intrinsic apoptotic pathway played a 
more important role than the extrinsic pathway. 
Mitochondrion plays a pivotal role in the intrinsic apoptotic pathway which 
is initiated by the loss of A平m. The loss of A^m could increase the mitochondrial 
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membrane permeabilization, as a result, allowing the release of apoptogenic proteins, 
such as cytochrome c, into the cytosol. The cytoplasmic cytochrome c forms 
apoptosome with other proteins that could in-turn activate downstream caspase 
family proteases and ultimately lead to apoptotic cell death (Henry-Mowatt et al., 
2004). The impact on mitochondria membrane permeabilization was reported to be 
early effect in the apoptosis (Green and Reed, 1998; Zamzami et al., 1995). Several 
studies demonstrated the early depletion of A^m in apoptosis induced by 
selenocompounds (Chen and Wong, 2008a; Chen and Wong, 2009b; Xiang et al., 
2009). Consistent with the previous results, we showed that SeC-induced ATm 
disruption in LNCaP cells occurred only after 1 h of treatment (Fig. 11). 
Bd-2 family proteins are the key regulators of the A平m, controlling the 
movement of apoptogenic proteins into the cytosol. This family of proteins can be 
divided into two subgroups according to their functions: the pro-apoptotic members 
(Bax, Bad, Bik, Bak, Bid, Bim, Noxa, Puma, etc.) and anti-apoptotic members (Bcl-2, 
Bcl-xL, Mcl-l, etc.). The anti-apoptotic members such as Bcl-2 and Bcl-xL can 
prevent the apoptogenic proteins from entering the cytosol. The pro-apoptotic 
members function by either blocking the action of the anti-apoptotic members or 
activating other pro-apoptotic members (Hengartner, 2000; Henry-Mowatt et al., 
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2004). 
Data in Fig. 12 showed decreased expression of full length Bid and 
significant up-regulation of Bak and Bax expression. The results indicated the 
existence of cross talk between the extrinsic and intrinsic apoptotic pathways. 
Cleavage of Bid by caspase-8/10 produces active truncated Bid (tBid) which can 
translocate to the outer mitochondrial membrane (OMM) and act on Bax and/or Bak. 
Truncated Bid could elicit Bax oligomerization and insertion into the OMM and/or 
Bak oligomerization. The formation of channels by Bax or Bak allows the release of 
apoptogenic proteins out of mitochondria (Antonsson et al., 2001; Eskes et al., 2000). 
As shown ill Fig. 12 and 13, Bax, Puma and Noxa were remarkably up-regulated and 
Bcl-2 and Mcl-l were down-regulated after exposure to SeC. The data suggested the 
involvement of p53 in regulating the A中m since Bax, Puma and Bcl-2 are 
downstream targets of p53 protein in the signaling pathway. 
The role of the tumour suppressor gene p53 in controlling apoptosis has 
been well documented. In response to multiple stress signals such as DNA damage, 
UV light or hypoxia, p53 gene is activated to induce cell cycle arrest, DNA repair 
and apoptosis. The apoptotic inducing ability of p53 is tightly regulated. 
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Phosphorylation of specific amino acids of the p53 protein has been related to 
apoptosis (Fridman and Lowe, 2003; Siliciano et al., 1997). 
Our western blot results demonstrated that proteolytic expression of total 
p53 proteins, p-p53 (Ser 15) and p-p53 (Ser 392) were significantly increased in 
SeC-treated LNCaP cells (Fig. 14). The p53 protein was also found to be 
phosphorylated at serine 15 and 392 in other types of cancer cells treated with SeC 
(Chen and Wong, 2008a, Chen and Wong 2009b). Phosphorylation at Ser 15 of p53 
has been shown to occur after DNA damage; as a result, the interaction of p53 with 
its negative regulator (oncoprotein MDM2) was reduced (Shieh et al , 1997). And 
phosphorylation of p53 at Ser392 was found to be required for the growth 
suppressing and DNA binding function of p53 (Hao et al., 1996). p53 executes pro-
apoptotic effect either via transcription-dependent or -independent signaling 
(Fridman and Lowe, 2003). In transcription-dependent signaling pathway, p53 
regulates the transcription of downstream target genes such as pro-apoptotic genes: 
Bax, Puma and Noxa, and anti-apoptotic genes: Bcl-2 and Bcl-xL. In the present 
study, the up-regulation of Bax, Puma and Noxa, and down-regulation of Bcl-2 and 
Mcl-1 (Fig. 12, 13) were activated by p53. These results suggested that p53 
responded to SeC via the transcription-dependent pathway. 
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PDK/Akt and MAPK signaling pathways have been demonstrated to 
regulate the apoptotic induction effect of selenocompounds in human prostate cancer 
cells (Chen and Wong, 2008b; Hu et al., 2005; Jiang et al., 2002). PDK/Akt signaling 
pathway is important in mediating cell proliferation. Over-expression of the protein 
kinase Akt has been shown in many cancer cell types promoting cell division and 
inhibiting apoptosis, thereby promoting tumour cells growth (Lawlor and Alessi, 
2001). The MAPKs comprise three serine-threonine kinases, including the ERK, 
JNK/SAPKs and p38 MAPK. The MAPKs are important protein kinases which 
direct extracellular signals into intracellular responses. These protein kinases are 
stress activated (Ramachandiran et al., 2002). ERKs are generally considered as 
survival mediators controlling cell proliferation and differentiation. They are 
activated to inhibit apoptosis and enhance cell growth by UV irradiation, oxidative 
stress, heat shock and virus infection (Johnson and Lapadat, 2002; Ramachandiran et 
al.，2002; Torres and Forman, 2003). JNK and p38 MAPK, on the other hand, are 
activated to induce apoptosis in response to various stresses such as inflammatory 
cytokines, oxidants, UV irradiation, heat shock and osmotic shock (Boldt et al., 
2002; Johnson and Lapadat, 2002; Ramachandiran et al., 2002; Torres and Forman, 
2003). However, the functions of these MAPKs vary according to the types of cell 
and stimuli. 
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In the present study, SeC exposure caused a differential activation of ERK, 
JNK, p38 MAPK and Akt, all of these kinases were phosphorylated with different 
extent (Fig. 16). The data from experiments using specific inhibitors of the kinases 
indicated that JNK and Akt played important roles while ERK and p38 MAPK did 
not play important roles in regulating SeC-induced apoptosis in LNCaP cells (Fig 17 
and 18). These results suggested that Akt played a role as a survival mediator while 
JNK as an apoptosis inducer contributing to SeC-induced apoptosis in LNCaP cells. 
The phosphorylation of pro-survival Akt might be due to the defense mechanism of 
the LNCaP cell which wants to survive from the apoptotic inducing effect exerted on 
it by SeC. The Akt counter-acted with the apoptosis induced by SeC and might 
inhibit the apoptosis in some extent. However, the pro-survival effect of 
phosphorylated Akt in LNCaP cells was not great enough to completely prevent the 
apoptosis induced by SeC. 
The results were supported with our previous findings and the works done 
by other researchers. In our previous study, we had demonstrated that SeC increased 
the phosphorylation of ERK in human breast adenocarcinoma MCF7 cells (Chen and 
Wong, 2008b). Hu et al. also found that methylseleninic acid and selenite increased 
the phosphorylation of ERK in LNCaP cells (Hu et al , 2005). Moreover, studies of 
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Jiang et al. showed that selenite activated the phosphorylation of JNK and p38 
MAPK in DU145 human prostate cancer cells (Jiang et al., 2002). Both studies of 
Jiang et al. and Hu et al. also demonstrated that selenite increased the 
phosphorylation of Akt in DU145 cells and LNCaP cells respectively. 
To further explore the relationship between the phosphorylation of the 
apoptotic inducer JNK and SeC-induced apoptotic pathway, we compared the time-
course of changes of JNK phosphorylation with PARP cleavage in SeC-treated 
LNCaP cells (Fig. 9 and 16). Slight phosphorylation of JNK onset after 1 h of SeC 
treatment, meanwhile, PARP was also slightly cleaved. The phosphorylation level of 
JNK continued to increase and became significant at 4 h; later, apoptosis was onset 
as revealed by the significant cleavage of PARP at 8 h. These results suggested a 
connection between the JNK signaling pathway with SeC-induced apoptosis. 
Numerous studies reported that selenocompounds induce apoptosis in 
prostate cancers by generating superoxide (Xiang et al., 2009; Zhao et al., 2006a; 
Zhao et al., 2006b). Superoxide (O2"), also known as hyperoxide, is the product of 
one-electron reduction of O2. In mammalian cells, the major source of superoxide is 
produced at the mitochondria (Gonzalez et al., 2007; Green and Reed, 1998). The 
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depletion of A平m observed in the SeC-treated LNCaP cell (Fig. 11) suggested us to 
measure the level of superoxide in the cells. In addition to that, growing evidences 
suggested that oxidative stress activates various signaling pathways such as the 
MAPK and PI3K/Akt signaling pathways (Ramachandiran et al., 2002; Torres and 
Forman, 2003). Therefore, we investigated whether superoxide was generated in 
LNCaP cells exposed to SeC. 
As predicted, dramatic generation of superoxide was found in LNCaP cells 
in a dose- and time-dependent manner (Fig. 19, 20). As demonstrated in the time-
course studies (Fig. 11, 20)，SeC-induced superoxide generation occurred earlier than 
SeC-induced A平m depletion. These results established a causal relationship between 
superoxide and and suggested mitochondria as a mediator of SeC-induced 
apoptosis. Pre-treatment of antioxidant NAC significantly blocked the generation of 
superoxide in SeC-treated LNCaP cells (Fig. 21). In addition to acting as free radical 
scavengers, NAC has also been demonstrated to act as precursor of thiol-reducing 
agent like glutathione (GSH) (Valko et al , 2007). Moreover, a previous study 
showed that treatment of SeC in cancer cell was related to depletion of intracellular 
GSH level (Batist et al., 1986). Taken together, we suggested that SeC might exert 
anticancer effect by inactivating thiol-reducing agents such as GSH, thus cause 
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accumulation of superoxide in cells, which finally led to DNA damage and apoptosis 
in LNCaP cells. 
We further determined the importance of superoxide in SeC-induced 
apoptosis. The effects of NAC on SeC-induced sub-Gl cell accumulation, A中m 
depletion, caspases activation, PARP cleavage, MAPK signaling, PI3K/Akt signaling 
and overall apoptosis were investigated (Fig. 22-26). The results showed that NAC 
could significantly prevent the SeC-induced apoptosis as indicated by decreased sub-
Gl population, increased A^m, reduced caspases activation and PARP cleavage, and 
decreased ERK, JNK, p38 MAPK and Akt phosphorylation in LNCaP cells. These 
results suggested that superoxide generation was important and necessary in SeC-
induced apoptosis, and MAPK and PDK/Akt signaling pathways in LNCaP cells. 
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Chapter 5 Conclusion 
Prostate cancer is the most commonly diagnosed cancer in men of most 
western countries. Recently, the incidence rates of prostate cancer have risen rapidly 
in most countries including the low-risk Asian populations (Hsing et al., 2000; Sim 
and Cheng, 2005). The landmark clinical trial by Clark et al working on the 
preventive effect of Se supplementation on prostate cancer has provided the most 
promising evidence for the role of Se as a chemopreventive agent against prostate 
cancer (Clark et a l , 1998). Clark's prevention trial has motivated numerous 
researches studying the action mechanism of Se on prostate cancer. 
Naturally, Se compounds exist in inorganic and organic forms. The 
chemopreventive efficacies of Se compounds on prostate cancer are differently 
depending on the dose and form of the compounds (Nadiminty and Gao, 2008). 
Previously, we demonstrated SeC as a novel Se compounds exerting a broad-
spectrum of anticancer activities (Chen and Wong, 2009a). SeC exhibited toxicity in 
to a number of cancer cell lines including human leukemia HL-60 cells, human 
hepatoma HepG2 cells, human breast carcinoma MCF-7 cells and human melanoma 
A375 cells (Batist et al., 1986; Chen and Wong, 2008a; Chen and Wong, 2009a; Kim 
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et al., 2003). Moreover, an in vivo study showed that supplementation of SeC could 
significantly reduce nitrosamine induced lung tumors in A/J mouse (Li et al., 2005). 
Despite its potency in inhibiting cancer cell growth, the effects of SeC on prostate 
cancer cells have never been reported. In the present study, we have investigated the 
inhibitory effect of SeC on human prostate adenocarcinoma PC-3 cells and human 
carcinoma LNCaP cells. Results of MTT assay showed that SeC inhibited the growth 
of both prostate cancer cell lines. SeC induced dose- and time-dependent apoptosis in 
LNCaP cells but not in PC-3 cells. SeC-induced apoptosis in LNCaP cells occurred 
through extrinsic and intrinsic apoptotic pathways, as evidenced by activation of 
initiator caspase-10 and -9, followed by activation of effector caspase-3 and -7, 
cleavage of PARP, nuclear condensation, and DNA fragmentation. Pretreatment of 
caspase inhibitors could significantly reduce the SeC-induced formation of sub-Gl 
cells and apoptosis in LNCaP cells. These results indicate that SeC triggered caspase-
dependent apoptotic pathway in LNCaP cells. We also demonstrated that the intrinsic 
mitochondrial pathway played more important role in SeC-induced apoptosis in 
LNCaP cells. 
Moreover, SeC induced the depletion of A中m by regulating the expression 
of pro-surivival and pro-apoptotic Bcl-2 family members. In addition, exposure of 
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LNCaP cells to SeC resulted in an increase expression in total p53 and 
phosphorylated p53 on serine residues of Serl5 and Ser392. Activation of p53 up-
regulated the pro-apoptotic factors including Puma, Noxa, and Bax, and down-
regulated the pro-survival factor Bcl-2. 
Furthermore, time-course studies showed that a significant increase of 
superoxide was detected in the LNCaP cells treated with SeC for 5 min, indicating 
that superoxide generation was the upstream cellular event induced by SeC. 
Moreover, ERK, JNK, p38 MAPK and Akt were activated by phosphorylation 
induced by SeC. Pretreatment of inhibitor of Akt (LY294002) and JNK (SP600125) 
could regulate SeC-induced apoptosis, however, ERK (U0126) and p38 MAPK 
(SB203580) inhibitors did not alter apoptotic-inducing effect of SeC. Pretreatment of 
antioxidant NAC could significantly suppress the generation of superoxide, apoptosis, 
M A P K S and PI3K/Akt signaling. Collectively, SeC induced superoxide-mediated 
apoptosis, MAPK and PI3K/Akt signaling pathways in LNCaP cells. These results 
suggest SeC as a promising selenocompound in treating prostate cancer. 
In this study, the in vitro mechanism of SeC action was elucidated (Fig. 27) 
which indicated that SeC could inhibit the growth of prostate cancer in vitro. 
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However, since there are some clinical trial studies (Lippman et al., 2009; Stratton et 
al., 2010) suggesting that SeC supplementation could not prevent prostate cancer, the 
examination of the prostate cancer preventive effect in vivo should be carried out. 
The contradiction in the results from clinical trials and the in vitro results may be due 
to a number of possible factors. First, the clinical trial used selenium-enriched yeast 
which was a mixture of selenium compounds that would dilute the chemopreventive 
effect of the selenium compounds which would, on the other hand, show strong 
inhibitory effect on prostate cancer cells. Second, the supplemented selenium-
enriched yeast might be metabolized into other forms of selenium compounds in the 
body which was not considered in the in vitro cell model. Therefore, in the future, in 
vivo nude mice xenograft experiment should be carried out to study the overall 
apoptotic effect of SeC on the living system of nude mice. Besides studying the 
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Figure 27. Proposed apoptotic pathways induced by SeC in LNCaP cells. 
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